Literature DB >> 31479104

Association Between Data Sources and US Food and Drug Administration Drug Safety Communications.

Noam Tau1,2, Tzippy Shochat3, Anat Gafter-Gvili2,4, Ariadna Tibau5, Eitan Amir6, Daniel Shepshelovich2,4.   

Abstract

Year:  2019        PMID： 31479104      PMCID： PMC6724416          DOI： 10.1001/jamainternmed.2019.3066

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  8 in total

1.  US Food and Drug Administration Safety Advisories and Reporting to the Adverse Event Reporting System (FAERS).

Authors:  Thomas J Moore; Richard L Morrow; Colin R Dormuth; Barbara Mintzes
Journal:  Pharmaceut Med       Date:  2020-04

Review 2. 

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

3.  Reporting of clinical trial safety results in ClinicalTrials.gov for FDA-approved drugs: A cross-sectional analysis.

Authors:  Krista Y Chen; Erin M Borglund; Emma Charlotte Postema; Adam G Dunn; Florence T Bourgeois
Journal:  Clin Trials       Date:  2022-04-28       Impact factor: 2.599

Review 4.  Update on the adverse effects of antimicrobial therapies in community practice.

Authors:  Samiha Mohsen; James A Dickinson; Ranjani Somayaji
Journal:  Can Fam Physician       Date:  2020-09       Impact factor: 3.275

5.  A stratification method based on clustering for the minimization of data masking effect in signal detection.

Authors:  Jian-Xiang Wei; Yue Ding; Ming Li; Jun Sun
Journal:  BMC Med Inform Decis Mak       Date:  2020-02-03       Impact factor: 2.796

6.  Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.

Authors:  Min Fan; Adrienne Y L Chan; Vincent K C Yan; Xinning Tong; Lauren K W Lau; Eric Y F Wan; Eliza Y T Tam; Patrick Ip; Terry Y Lum; Ian C K Wong; X Li
Journal:  Orphanet J Rare Dis       Date:  2022-01-04       Impact factor: 4.123

7.  Characterization and corroboration of safety signals identified from the US Food and Drug Administration Adverse Event Reporting System, 2008-19: cross sectional study.

Authors:  Meera M Dhodapkar; Xiaoting Shi; Reshma Ramachandran; Evan M Chen; Joshua D Wallach; Joseph S Ross
Journal:  BMJ       Date:  2022-10-05

8.  Signals of adverse drug reactions communicated by pharmacovigilance stakeholders: protocol for a scoping review of the global literature.

Authors:  Daniele Sartori; Jeffrey K Aronson; Igho J Onakpoya
Journal:  Syst Rev       Date:  2020-08-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.